Business
ALX Oncology Advances Separate Clinical Trials Evaluating Investigational CD47-Inhibitor Evorpacept and Novel EGFR-Targeted Antibody-Drug Conjugate ALX2004
- First patient dosed in Phase 2 ASPEN-09-Breast trial evaluating evorpacept in combination with trastuzumab and physician’s choice of chemotherapy in HER2-positive metastatic breast cancer; interim analysis anticipated Q3 2026 – - Third dose cohort initiated in Phase 1 trial of ALX 2004; study remains on track to provide initial safety data in 1H 2026 - SOUTH SAN FRANCISCO, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. (“ALX Oncology,” Nasdaq: ALXO), a clinical-stage biot
About this update from Alx Oncology Holdings Inc.
[{"type":"image","alt":"ALX Oncology","displaySize":"","headline":null,"caption":"ALX Oncology","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":195,"url":"https://media.zenfs.com/en/globenewswire.com/470f956a3deddaf81b04c64bb1806e3d"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/tBYkx9_bHbgV6zgiof22Rw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTI3MztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/470f956a3deddaf81b04c64bb1806e3d","width":300,"height":195}},"lazy":false},{"type":"text","content":"- First patient dosed in Phase 2 ASPEN-09-Breast trial evaluating evorpacept in combination with trastuzumab and physician’s choice of chemotherapy in HER2-positive metastatic breast cancer; interim analysis anticipated Q3 2026 –","length":229,"tagName":"p"},{"type":"text","content":"- Third dose cohort initiated in Phase 1 trial of ALX 2004; study remains on track to provide initial safety data in 1H 2026 -","length":126,"tagName":"p"},{"type":"text","content":"SOUTH SAN FRANCISCO, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. (“ALX Oncology,” Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives, announced that the first patient has been dosed in the Company’s Phase 2 ASPEN-09-Breast trial evaluating its investigational CD47-inhibitor evorpacept. This trial will evaluate the combination of evorpacept with trastuzumab and physicians’ choice of chemotherapy in patients with HER2-positive metastatic breast cancer whose disease has progressed after ENHERTU® (T-DXd).","length":626,"tagName":"p"},{"type":"text","content":"Additionally, after successfully clearing the second dose cohort, the Phase 1 trial evaluating the Company’s epidermal growth factor receptor (EGFR)-targeted antibody-drug conjugate (ADC) ALX2004 for the treatment of EGFR-expressing solid tumors has begun enrolling patients in the third dose cohort at 4mg/kg. No dose-limiting toxicities were observed in the prior two dose cohorts.","length":383,"tagName":"p"},{"type":"text","content":"“We are extremely pleased with the progress we are making on these clinical trials,” said Jason Lettmann, Chief Executive Officer at ALX Oncology. “We believe both evorpacept and ALX2004 have the potential to fill significant gaps in the standard of care for many ty...